Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

511 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.
Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT. Lenhard JR, et al. Among authors: shin bs. J Antimicrob Chemother. 2017 Jan;72(1):153-165. doi: 10.1093/jac/dkw355. Epub 2016 Sep 15. J Antimicrob Chemother. 2017. PMID: 27634916 Free PMC article.
Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.
Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, Nation RL, Bulitta JB. Landersdorfer CB, et al. Among authors: shin bs. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02053-17. doi: 10.1128/AAC.02053-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29339388 Free PMC article.
Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB. Landersdorfer CB, et al. Among authors: shin bs. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02055-17. doi: 10.1128/AAC.02055-17. Print 2018 Apr. Antimicrob Agents Chemother. 2018. PMID: 29437610 Free PMC article.
Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.
Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB. Bulitta JB, et al. Among authors: shin bs. Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Clin Pharmacokinet. 2019. PMID: 29936678 Review.
Comprehensive stability analysis of 13 β-lactams and β-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation.
Zhou J, Qian Y, Lang Y, Zhang Y, Tao X, Moya B, Sayed ARM, Landersdorfer CB, Shin E, Werkman C, Smith NM, Kim TH, Kumaraswamy M, Shin BS, Tsuji BT, Bonomo RA, Lee RE, Bulitta JB. Zhou J, et al. Among authors: shin e, shin bs. Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0139923. doi: 10.1128/aac.01399-23. Epub 2024 Feb 8. Antimicrob Agents Chemother. 2024. PMID: 38329330
Population pharmacokinetics of a novel histone deacetylase inhibitor, cyclo{(2S)-2-amino-8-[(aminocarbonyl)hydrazono] decanoyl-1-L-tryptophyl-L-isoleucyl-(2R)-2-piperidinecarbonyl} (SD-2007), and its metabolic conversion to apicidin after intravenous injection and oral administration in rats.
Shin BS, Bulitta JB, Hong DK, Kim HY, Kim MK, Choi Y, Lee JB, Hwang SW, Lee MH, Yoo SD. Shin BS, et al. Chemotherapy. 2011;57(3):259-67. doi: 10.1159/000328027. Epub 2011 May 19. Chemotherapy. 2011. PMID: 21597290
511 results